Philip Young

Lobe Sciences Provides Company Review of 2023

Retrieved on: 
Monday, January 8, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Pharmacokinetics, Acquisition, Conference, Psilocybin, Sickle cell disease, Therapy, OTCQB, Philip Young, Pharmaceutical industry

Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company on its progress and achievements in 2023.

Key Points: 
  • Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company on its progress and achievements in 2023.
  • Philip Young CEO commented, “2023 was a remarkable year that witnessed the company make important advancements in clinical development of our proprietary pharmaceutical products and the acquisition and commercial launch of Altemia, our novel medical formulation for Sickle Cell Disease.”
    Confirmed the improved pharmacokinetics of L-130 delivered as a shelf-stable capsule over its inactive prodrug, psilocybin
    “2023 was truly a transformative year for Lobe Sciences.
  • The company plans to build on this momentum in 2024 and I look forward to updating our investors throughout 2024.”
    Management will be meeting with prospective investors and corporate partners during the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 8-11.
  • To schedule a meeting please contact [email protected]

Lobe Sciences Invites You to Join Us at the Q4 Virtual Investor Summit

Retrieved on: 
Monday, November 8, 2021
Concussion, OTC Markets Group, CEO, PTSD, Philip Young, Post-traumatic stress disorder, FDA, Therapy, Pharmaceutical industry

Vancouver, British Columbia--(Newsfile Corp. - November 8, 2021) - Lobe Sciences (OTC Pink: GTSIF) today announced that Philip Young, CEO & Director will be attending the Q4 Virtual Investor Summit.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - November 8, 2021) - Lobe Sciences (OTC Pink: GTSIF) today announced that Philip Young, CEO & Director will be attending the Q4 Virtual Investor Summit.
  • Millions of people are experiencing the devastating, often long-term effects of mTBI (mild traumatic brain injury) and PTSD (post-traumatic stress disorder), with few, if any, effective treatments available.
  • Our goal is to change that fact, and during this presentation, Philip Young, CEO & Director, will outline a path for the development of therapeutics for which Lobe Sciences intends to seek FDA approval in the United States, and similar approvals internationally.

Lobe Sciences Appoints Albert "Skip" Rizzo, Ph.D to Scientific Advisory Board

Retrieved on: 
Monday, August 23, 2021
Industry, Company, University, CSE, Growth, NAC, Medicine, School, Science, Research, THIS, Century, Philip Young, Forward-looking statement, VR, TBI, Alzheimer's disease, Mental health, ADHD, Creative Technology, SAB, Board, Coronavirus Scientific Advisory Board (Turkey), Rehabilitation, Psychiatry, OTC Markets Group, News, Patient, CEO, Psilocybin, THE, Stroke, PTSD, Virtual reality, Pharmaceutical industry, Audit

Vancouver, British Columbia--(Newsfile Corp. - August 23, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Albert "Skip" Rizzo, Ph.D, to its Scientific Advisory Board.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - August 23, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Albert "Skip" Rizzo, Ph.D, to its Scientific Advisory Board.
  • Philip Young, CEO and Director of Lobe stated, "We are extremely happy to have an industry leading Virtual Reality (VR) expert joining our Scientific Advisory Board, and look forward to his contributions on our clinical development and the creation of our Krysalis Therapeutic Pod."
  • Albert "Skip" Rizzo is a clinical psychologist and Director of Medical VR at the University of Southern California Institute for Creative Technologies.
  • Lobe Sciences is a life sciences company focused on psychedelic medicines.